| Dr Russell Bryan Bacak, MD | |
|
2911 Texas Ave S Ste 202, College Station, TX 77845-5388 | |
| (979) 695-3570 | |
| (979) 695-3573 |
| Full Name | Dr Russell Bryan Bacak |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 2911 Texas Ave S Ste 202, College Station, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184705741 | NPI | - | NPPES |
| 116306506 | Medicaid | TX | |
| P00139188 | Other | TX | MEDICARE RAILROAD |
| 8M1860 | Other | TX | BLUE CROSS NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | K5445 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Traditions Health Care | College station, TX | Home health agency |
| Healthquest | Bryan, TX | Home health agency |
| St Joseph Regional Health Center | Bryan, TX | Hospital |
| Physicians Centre,the | Bryan, TX | Hospital |
| Baylor Scott & White Medical Center- College Stati | College station, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bcs Abundant Life Family Practice | 8123006772 | 3 |
| Texas Aandm University System Health Science Center | 8224008644 | 35 |
News Archive
Mylan Inc. today announced its financial results for the three months ended March 31, 2011.
BrainScope Company, today announced its sponsorship of a multi-center, observational clinical study, the "B-Ahead U.K. Trial", utilizing its technology in development to aid in the assessment of traumatic brain injury and its milder forms in emergency departments in the United Kingdom.
In a study appearing in the September 13 issue of JAMA, Jouke T. Annema, M.D., Ph.D., of the Academic Medical Center, Amsterdam, and colleagues examined five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer.
Targeting the emergent field of hyperspectral retinal imaging, Photon etc. is proud to launch IRIS™, a new device for non-invasive localization of biomolecules in the eye fundus. Based on a custom-made mydriatic retinal camera and Photon etc.'s Tunable Laser Source, IRIS™ is a versatile instrument that allows high definition retinal imaging at any wavelength from 420 to 1000 nm. IRIS™ is the ideal research tool to better understand and develop tomorrow's treatments for retinal diseases, such as diabetic retinopathy and age-related macular degeneration. This product is sold for research purposes only.
Findings from a new study led by researchers at Dartmouth's Geisel School of Medicine and Harvard Medical School and published in the journal Circulation: Cardiovascular Quality and Outcomes, show that the way in which pharmaceutical companies are permitted to share information about their drugs can influence physician prescribing practices.
› Verified 9 days ago
| Entity Name | St Joseph Regional Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669557179 PECOS PAC ID: 5294727921 Enrollment ID: O20040401000670 |
News Archive
Mylan Inc. today announced its financial results for the three months ended March 31, 2011.
BrainScope Company, today announced its sponsorship of a multi-center, observational clinical study, the "B-Ahead U.K. Trial", utilizing its technology in development to aid in the assessment of traumatic brain injury and its milder forms in emergency departments in the United Kingdom.
In a study appearing in the September 13 issue of JAMA, Jouke T. Annema, M.D., Ph.D., of the Academic Medical Center, Amsterdam, and colleagues examined five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer.
Targeting the emergent field of hyperspectral retinal imaging, Photon etc. is proud to launch IRIS™, a new device for non-invasive localization of biomolecules in the eye fundus. Based on a custom-made mydriatic retinal camera and Photon etc.'s Tunable Laser Source, IRIS™ is a versatile instrument that allows high definition retinal imaging at any wavelength from 420 to 1000 nm. IRIS™ is the ideal research tool to better understand and develop tomorrow's treatments for retinal diseases, such as diabetic retinopathy and age-related macular degeneration. This product is sold for research purposes only.
Findings from a new study led by researchers at Dartmouth's Geisel School of Medicine and Harvard Medical School and published in the journal Circulation: Cardiovascular Quality and Outcomes, show that the way in which pharmaceutical companies are permitted to share information about their drugs can influence physician prescribing practices.
› Verified 9 days ago
| Entity Name | Bcs Abundant Life Family Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689755266 PECOS PAC ID: 8123006772 Enrollment ID: O20040709001045 |
News Archive
Mylan Inc. today announced its financial results for the three months ended March 31, 2011.
BrainScope Company, today announced its sponsorship of a multi-center, observational clinical study, the "B-Ahead U.K. Trial", utilizing its technology in development to aid in the assessment of traumatic brain injury and its milder forms in emergency departments in the United Kingdom.
In a study appearing in the September 13 issue of JAMA, Jouke T. Annema, M.D., Ph.D., of the Academic Medical Center, Amsterdam, and colleagues examined five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer.
Targeting the emergent field of hyperspectral retinal imaging, Photon etc. is proud to launch IRIS™, a new device for non-invasive localization of biomolecules in the eye fundus. Based on a custom-made mydriatic retinal camera and Photon etc.'s Tunable Laser Source, IRIS™ is a versatile instrument that allows high definition retinal imaging at any wavelength from 420 to 1000 nm. IRIS™ is the ideal research tool to better understand and develop tomorrow's treatments for retinal diseases, such as diabetic retinopathy and age-related macular degeneration. This product is sold for research purposes only.
Findings from a new study led by researchers at Dartmouth's Geisel School of Medicine and Harvard Medical School and published in the journal Circulation: Cardiovascular Quality and Outcomes, show that the way in which pharmaceutical companies are permitted to share information about their drugs can influence physician prescribing practices.
› Verified 9 days ago
| Entity Name | Texas A&m University System Health Science Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063699312 PECOS PAC ID: 8224008644 Enrollment ID: O20040802001578 |
News Archive
Mylan Inc. today announced its financial results for the three months ended March 31, 2011.
BrainScope Company, today announced its sponsorship of a multi-center, observational clinical study, the "B-Ahead U.K. Trial", utilizing its technology in development to aid in the assessment of traumatic brain injury and its milder forms in emergency departments in the United Kingdom.
In a study appearing in the September 13 issue of JAMA, Jouke T. Annema, M.D., Ph.D., of the Academic Medical Center, Amsterdam, and colleagues examined five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer.
Targeting the emergent field of hyperspectral retinal imaging, Photon etc. is proud to launch IRIS™, a new device for non-invasive localization of biomolecules in the eye fundus. Based on a custom-made mydriatic retinal camera and Photon etc.'s Tunable Laser Source, IRIS™ is a versatile instrument that allows high definition retinal imaging at any wavelength from 420 to 1000 nm. IRIS™ is the ideal research tool to better understand and develop tomorrow's treatments for retinal diseases, such as diabetic retinopathy and age-related macular degeneration. This product is sold for research purposes only.
Findings from a new study led by researchers at Dartmouth's Geisel School of Medicine and Harvard Medical School and published in the journal Circulation: Cardiovascular Quality and Outcomes, show that the way in which pharmaceutical companies are permitted to share information about their drugs can influence physician prescribing practices.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Russell Bryan Bacak, MD 2911 Texas Ave S Ste 202, College Station, TX 77845-5388 Ph: (979) 695-3570 | Dr Russell Bryan Bacak, MD 2911 Texas Ave S Ste 202, College Station, TX 77845-5388 Ph: (979) 695-3570 |
News Archive
Mylan Inc. today announced its financial results for the three months ended March 31, 2011.
BrainScope Company, today announced its sponsorship of a multi-center, observational clinical study, the "B-Ahead U.K. Trial", utilizing its technology in development to aid in the assessment of traumatic brain injury and its milder forms in emergency departments in the United Kingdom.
In a study appearing in the September 13 issue of JAMA, Jouke T. Annema, M.D., Ph.D., of the Academic Medical Center, Amsterdam, and colleagues examined five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer.
Targeting the emergent field of hyperspectral retinal imaging, Photon etc. is proud to launch IRIS™, a new device for non-invasive localization of biomolecules in the eye fundus. Based on a custom-made mydriatic retinal camera and Photon etc.'s Tunable Laser Source, IRIS™ is a versatile instrument that allows high definition retinal imaging at any wavelength from 420 to 1000 nm. IRIS™ is the ideal research tool to better understand and develop tomorrow's treatments for retinal diseases, such as diabetic retinopathy and age-related macular degeneration. This product is sold for research purposes only.
Findings from a new study led by researchers at Dartmouth's Geisel School of Medicine and Harvard Medical School and published in the journal Circulation: Cardiovascular Quality and Outcomes, show that the way in which pharmaceutical companies are permitted to share information about their drugs can influence physician prescribing practices.
› Verified 9 days ago
Dr. Van Thi Ngo, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 University Dr E, College Station, TX 77840 Phone: 979-691-3300 | |
Dr. Bo Xuan, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: A P Beutel Health Center, Texas A&m University, College Station, TX 77843 Phone: 979-458-8269 Fax: 979-458-8352 | |
Laura Muehr, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 University Dr E Ste 100, College Station, TX 77840 Phone: 979-691-3300 Fax: 979-691-3527 | |
Dr. Gary Lambert, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1602 Rock Prairie Rd, Ste. 1100, College Station, TX 77845 Phone: 979-693-2586 Fax: 979-693-7327 | |
Dr. Adel A Massoud, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4421 Highway 6 S, College Station, TX 77845 Phone: 979-690-4260 Fax: 979-690-4476 | |
Dr. Mark Stanley Higgins, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 University Dr E, College Station, TX 77840 Phone: 409-691-3300 | |
Dr. Donald Raymond Gehring, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1700 University Dr E, College Station, TX 77840 Phone: 979-691-3300 |